Curated by THEOUTPOST
On Thu, 5 Dec, 8:03 AM UTC
4 Sources
[1]
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations By Investing.com
NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: NASDAQ:ICAD) (iCAD or the Company) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), taking place from December 10-13, 2024. These clinical abstracts highlight the latest research in breast health AI, focusing on improving detection and risk prediction accuracy and assessing disparities across diverse populations. Presenting Author Chirag R. Parghi, MD, MBA, Chief Medical (TASE:PMCN) Officer at Solis Mammography, will showcase three research abstracts during Poster Session 2, scheduled for Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CST. Additional contributing authors include Jennifer Pantleo, R.N., BSN; Julie Shisler, BS; Jeff Hoffmeister, M.D., MSEE; Zi Zhang, M.D., M.P.H; Avi (JO:AVIJ) Sharma, M.D.; and, Wei Zhang, PhD. Additionally, presenting Author Mikael Eriksson, PhD, epidemiologist at Karolinska Institute, Sweden, will present research during general session 2, scheduled for Thursday, December 12, 2024 from 9:00 a.m. to 12:30 p.m. CST. demonstrating a 10-year image-derived AI-risk model, based on iCAD's ProFound Risk solution, for primary prevention of breast cancer showed higher discriminatory performance than the clinical Tyrer-Cuzick v8 risk model. Advancing Breast Health with AI These studies exemplify the critical role the ProFound AI Breast Health Suite can play in not only improving early breast cancer detection and risk prediction but also in addressing health disparities in diverse populations, said Dana Brown, President and CEO of iCAD. We are proud to collaborate with Solis Mammography and Karolinska Institute contributing to groundbreaking research that can elevate the standard of care in breast health worldwide. These partnerships demonstrate the potential of our technology to improve patient outcomes, and also opens pathways to broader adoption of AI in healthcare, driving growth in key markets. Dr. Chirag Parghi, Chief Medical Officer at Solis Mammography, added: These findings underscore the transformative potential of AI in empowering clinicians to improve outcomes regardless of age, race or breast density. By addressing traditional gaps in breast cancer detection and risk assessment, AI has the potential to exponentially improve current and future state breast cancer detection. Poster Details: P2-06-20: Use of an AI Algorithm to Determine the Prevalence of Breast Arterial Calcifications in Women Undergoing Screening Mammograms Based on Race, Age, and Cancer Status (SESS-2141) This poster explores the potential of an AI algorithm to identify Breast Arterial Calcifications (BAC), which are calcium deposits in the arteries of the breast that are commonly detected during routine mammograms. The study demonstrates that the weighted prevalence and distribution of BAC increases with age, as expected in a screening population. Interestingly, BAC prevalence did not vary by race, suggesting that it could serve as an effective cardiovascular biomarker across racial groups. Furthermore, the AI-based BAC detection algorithm highlighted a higher prevalence of BAC in women with mammographically detected breast cancer, suggesting women with increased BAC and breast cancer may benefit from cardiovascular assessment in addition to their oncological treatment. In that sense, a conventional mammogram could identify the cardiac needs of patients prior to or at the time of breast cancer diagnosis, providing an opportunity for early cardiovascular intervention. P2-06-24: Effect of an Image-Derived Short-Term Breast Cancer Risk Score in the Analysis of Breast Cancer Prevalence in Screening Populations by Race and Breast Density (SESS-2148) This study delves into the development and validation of an AI-driven short-term breast cancer risk assessment score based on image-derived features, including mammographic density, and age. AI-generated case scores were shown to effectively stratify mammograms into categories with varying frequencies of cancer. The case scores did not vary significantly across racial subgroups in our dataset, suggesting that the accuracy of the AI software was consistent across races. The study concludes that an image-derived AI risk model is equally effective across race and density, providing accurate insight into short-term breast cancer risk. Based on the results, image-based risk scoring could offset known gaps in breast cancer detection by traditional mammography in patients with dense breast tissue and help address existing disparities across races. Findings from this study highlight the potential of AI to offer more consistent and equitable breast cancer risk assessments, improving both diagnostic accuracy and patient outcomes across diverse populations. P2-06-25: Is Mammography Artificial Intelligence Consistent Across Race and Density? (SESS-2135) This research focuses on the consistency of AI-based mammographic case scoring across different racial and breast density groups. The study emphasizes the potential of AI to provide equitable and reliable screening results, regardless of the patient's race or breast tissue density, two factors known to impact traditional mammography outcomes. For women with non-dense or fatty breast tissue, a low case score corresponded to a significantly lower frequency of cancer (1 in 11,363) compared to women with dense breast tissue who had a low case score (1 in 1,952). Although this finding was not statistically significant according to the Mann-Whitney U test, the difference between categories is notable, and the lack of statistical confirmation is likely due to the low absolute number of cancer cases in the low case score, non-dense cohort. Therefore, the negative predictive value of a low case score on a screening mammogram is presumably higher in women with non-dense breast tissue across a large dataset, suggesting a more reliable assessment for this group. GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer The research analyzed a two-site case-cohort of women aged 30-90 in a population-based screening study in Minnesota and the KARMA cohort from Sweden using an image-derived AI-risk model compared with the clinical Tyrer-Cuzick v8 model using clinical guidelines. Analyses were performed for risk of all breast cancer and restricted to invasive cancer alone. Using the National Institute for Health and Care Excellence (NICE) guidelines, considering women at 8% as high risk, 32% of breast cancers could be subject to preventive strategies in the 9.7% of women at high 10-year risk based on the AI risk model, the 10-year image-derived AI-risk model showed good discriminatory performance and calibration in the two case-cohorts and, showed a significantly higher discriminatory performance than the clinical Tyrer-Cuzick v8 risk model in KARMA. Demonstrating the image-derived AI-risk model has the potential for clinical use in primary prevention and targets up to one third of breast cancers. Join Us at SABCS 2024 Attendees are invited to view these posters during Poster Session 2 on December 11, 2024, from 5:30 to 7:00 p.m. CST. To learn more about iCAD's AI solutions, including the ProFound AI Breast Health Suite, visit iCAD's website or contact iCAD for an interview at SABCS. About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. ProFound Detection v4 is FDA Cleared. ProFound AI v3 is FDA Cleared. CE Marked. Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed. Solutions may not be available in all geographies. Forward-Looking Statements Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI ®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov.
[2]
CORRECTION - iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 - icad (NASDAQ:ICAD)
NASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD, Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark "SecondReadAI" by Lunit, Inc. The corrected release follows: iCAD, Inc. ICAD ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions. iCAD and Cascaid Health Partner to Expand Access to AI-Driven Breast Health In alignment with their vision to enable all women to access to AI-powered breast health services, iCAD and Cascaid Health will unveil their collaboration to integrate the ProFound AI Breast Health Suite into Cascaid's leading edge digital health marketplace and access to care platform. Scheduled for beta launch in Q1 2025, this partnership between iCAD and Cascaid Health will launch ProFound Health, a virtual care model powered by Cascaid. ProFound Health will enable women who have not otherwise received an AI-read on their screening mammogram to access iCAD's advanced breast health technology. The initiative reflects both companies' dedication to democratizing access to life-saving technology and creating a world where cancer can't hide. ProFound Health partnership will offer virtual second reads of mammograms leveraging ProFound AI Breast Health Suite, an AI service providing patients without access to AI an opportunity to receive enhanced breast health insights. The initial service will include a second read detection, breast density assessment, and cancer risk evaluation from a Cascaid-affiliated specialist network of clinical experts in women's health through Cascaid's seamlessly integrated digital platform. By combining AI insights with expert clinical reviews, ProFound Health ensures that patients everywhere, regardless of location, can receive precision screening and personalized care. "ProFound Health empowers patients with access to critical information about their mammograms and overall breast health, allowing them to make informed decisions and take control of their care journey," said Dana Brown, CEO and President of iCAD. "Our collaboration with Cascaid Health's network of clinicians and AI-powered solutions is part of our ongoing commitment to bridging gaps in breast cancer care, ensuring all patients everywhere can access the accuracy and timeliness of AI solutions, and ultimately transforming patient outcomes." "We believe that every woman should have access to the best possible information about her breast health and a high quality, personalized care plan to catch cancer early or prevent it altogether. Through our partnership with iCAD, we're addressing a critical need to improve access to advanced breast health services," said Dr. Candace Westgate, Director of Women's Health for Cascaid Health. "ProFound Health is more than just a technological innovation, it's a lifeline that empowers patients and healthcare providers with actionable insights, bridging care gaps and ensuring equitable access to precision screening and personalized breast cancer care." Advancing Next Generation AI Breast Health Solutions at RSNA 2024 In addition to ProFound Health, iCAD will feature its flagship ProFound Detection Version 4.0, which recently received FDA clearance. This next-generation AI solution enhances breast cancer detection by incorporating prior exams into current analysis, improving the detection of aggressive cancers by 22%, reducing cases with no marks by 18%, and providing clinicians with more reliable insights for better decision-making. "Every two minutes, someone loses their life to breast cancer -- a disease affecting over 2.3 million women annually. Early detection is critical, as five-year survival rates exceed 99% for stage 1 disease. Yet traditional mammography misses over 20% of breast cancers, particularly in dense tissue, resulting in potentially avoidable late-stage diagnoses," said Dana Brown, President and CEO of iCAD, Inc. "ProFound Detection Version 4 revolutionizes breast cancer detection by uniquely integrating prior exams into its analysis. This advanced capability enhances sensitivity, sharpens precision, and provides radiologists with a deeper, longitudinal view of a patient's breast health. By enabling earlier and more accurate detection, especially in dense tissue, ProFound Detection Version 4 sets a new standard in breast health AI, empowering providers to improve outcomes and save lives. Together with our strategic partnerships, we are advancing the fight against cancer and making a meaningful difference for patients worldwide." ICAD'S RSNA 2024 Program Highlights AI-Powered Insights: Advancing Cancer Detection Oral Abstract Presentation: "Real World Effect of Artificial Intelligence on Histopathology and Stage in Breast Cancer Screening" Presenter: Kathy Schilling, M.D., Boca Raton Regional HospitalWhen: Sunday, December 1 | 10:30-11:30 AMWhere: S406A: S2-SSBR01-6Details: Dr. Kathy Schilling discusses the experience with tenured radiologists on how the current use of ProFound AI improves cancer detection, even in women with dense breast tissue, compared to their performance prior to the implementation of AI. In addition, she will describe the decrease in the mean size and stage of cancers after the implementation, along with an increase in the diagnosis of lobular cancers. "The integration of ProFound AI alongside our nine dedicated breast radiologists has demonstrated remarkable improvements in cancer detection and patient outcomes across our imaging network," said Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital. "We've seen a 23% overall increase in cancer detection rates, a 4% rise in invasive cancer detection, and doubled rates of lobular cancer detection. ProFound AI also enhanced detection in dense breast tissue by 32%, reduced invasive cancer size by 12%, and lowered histopathologic stage with a 40% reduction in T2 tumors -- all without increasing DCIS diagnoses or recall rates. These advancements underscore the transformative potential of AI in improving early breast cancer detection, elevating patient care, and ultimately saving lives." AI Theater Presentation: "The Thin White Line: Which Calcifications Matter? Advances in AI Breast Cancer Detection" Presenter: Chirag R. Parghi, M.D., M.B.A., Solis MammographyWhen: Tuesday, December 3 | 1:00-1:20 PMWhere: AI Showcase Theater (South Hall A), Booth 5536Details: A look at how ProFound Detection's next-generation capabilities reduce uncertainty in interpreting calcifications on a mammogram by displaying 20% fewer marks related to vascular calcifications and 51% fewer marks related to non-vascular calcifications, leading to enhanced precision and accuracy. Collaborative Panels and Partner Showcases GE HealthCare Expert Corner: Seamless integration of ProFound AI with GE mammography systems to enhance workflow and detection capabilities. Daily at Booth 7330 (North Hall).Densitas Panel: "Elevating Patient Care through Quality Images & Precise Detection." Daily at Booth 4747 (South Hall).CancerIQ: Daily at Booth 4747(South Hall).Blackford Panel: "Enhancing Breast Cancer Care with AI." Tuesday, December 3, 2:30-2:50 PM at Booth 4729 (South Hall).CARPL.ai Breast AI Panel: Wednesday, December 4, 11:00 AM at Booth 5733 (South Hall). Customer Appreciation Event iCAD will be hosting a customer appreciation event, "AI in the Sky: Discover ProFound Insights & Breast Health Innovations," on Sunday, December 1, at 6:00 PM at VU Rooftop in Chicago. Network with industry experts, hear insights from key opinion leaders including iCAD's CEO and Board of Directors, and explore how iCAD's solutions are transforming breast health. Visit the iCAD RSNA 2024 event page for the latest updates, event details, and partnership announcements. About Cascaid Health Cascaid Health Inc. delivers a personalized, expert-driven proactive and preventative approach, supported by an integrated platform designed to promote longevity, detect issues early, reverse risks, and optimize healthspan for all. The company's platform offers a curated marketplace featuring innovative products, services, and access to world-class multidisciplinary experts in women's health, precision health, lifestyle medicine, wellness, and performance. Cascaid Health Inc. is committed to advancing health equity, ensuring that cutting-edge healthcare solutions are accessible to everyone. About iCAD, Inc. iCAD, Inc. ICAD is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov. CONTACTS Media Inquiries: pr@icadmed.com Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations icad@imsinvestorrelations.com Market News and Data brought to you by Benzinga APIs
[3]
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations - icad (NASDAQ:ICAD)
NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. ICAD ("iCAD" or the "Company") a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), taking place from December 10-13, 2024. These clinical abstracts highlight the latest research in breast health AI, focusing on improving detection and risk prediction accuracy and assessing disparities across diverse populations. Presenting Author Chirag R. Parghi, MD, MBA, Chief Medical Officer at Solis Mammography, will showcase three research abstracts during Poster Session 2, scheduled for Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CST. Additional contributing authors include Jennifer Pantleo, R.N., BSN; Julie Shisler, BS; Jeff Hoffmeister, M.D., MSEE; Zi Zhang, M.D., M.P.H; Avi Sharma, M.D.; and, Wei Zhang, PhD. Additionally, presenting Author Mikael Eriksson, PhD, epidemiologist at Karolinska Institute, Sweden, will present research during general session 2, scheduled for Thursday, December 12, 2024 from 9:00 a.m. to 12:30 p.m. CST. demonstrating a 10-year image-derived AI-risk model, based on iCAD's ProFound Risk solution, for primary prevention of breast cancer showed higher discriminatory performance than the clinical Tyrer-Cuzick v8 risk model. Advancing Breast Health with AI "These studies exemplify the critical role the ProFound AI Breast Health Suite can play in not only improving early breast cancer detection and risk prediction but also in addressing health disparities in diverse populations," said Dana Brown, President and CEO of iCAD. "We are proud to collaborate with Solis Mammography and Karolinska Institute contributing to groundbreaking research that can elevate the standard of care in breast health worldwide. These partnerships demonstrate the potential of our technology to improve patient outcomes, and also opens pathways to broader adoption of AI in healthcare, driving growth in key markets." Dr. Chirag Parghi, Chief Medical Officer at Solis Mammography, added: "These findings underscore the transformative potential of AI in empowering clinicians to improve outcomes regardless of age, race or breast density. By addressing traditional gaps in breast cancer detection and risk assessment, AI has the potential to exponentially improve current and future state breast cancer detection." Poster Details: P2-06-20: Use of an AI Algorithm to Determine the Prevalence of Breast Arterial Calcifications in Women Undergoing Screening Mammograms Based on Race, Age, and Cancer Status (SESS-2141) This poster explores the potential of an AI algorithm to identify Breast Arterial Calcifications (BAC), which are calcium deposits in the arteries of the breast that are commonly detected during routine mammograms. The study demonstrates that the weighted prevalence and distribution of BAC increases with age, as expected in a screening population. Interestingly, BAC prevalence did not vary by race, suggesting that it could serve as an effective cardiovascular biomarker across racial groups. Furthermore, the AI-based BAC detection algorithm highlighted a higher prevalence of BAC in women with mammographically detected breast cancer, suggesting women with increased BAC and breast cancer may benefit from cardiovascular assessment in addition to their oncological treatment. In that sense, a conventional mammogram could identify the cardiac needs of patients prior to or at the time of breast cancer diagnosis, providing an opportunity for early cardiovascular intervention. P2-06-24: Effect of an Image-Derived Short-Term Breast Cancer Risk Score in the Analysis of Breast Cancer Prevalence in Screening Populations by Race and Breast Density (SESS-2148) This study delves into the development and validation of an AI-driven short-term breast cancer risk assessment score based on image-derived features, including mammographic density, and age. AI-generated case scores were shown to effectively stratify mammograms into categories with varying frequencies of cancer. The case scores did not vary significantly across racial subgroups in our dataset, suggesting that the accuracy of the AI software was consistent across races. The study concludes that an image-derived AI risk model is equally effective across race and density, providing accurate insight into short-term breast cancer risk. Based on the results, image-based risk scoring could offset known gaps in breast cancer detection by traditional mammography in patients with dense breast tissue and help address existing disparities across races. Findings from this study highlight the potential of AI to offer more consistent and equitable breast cancer risk assessments, improving both diagnostic accuracy and patient outcomes across diverse populations. P2-06-25: Is Mammography Artificial Intelligence Consistent Across Race and Density? (SESS-2135) This research focuses on the consistency of AI-based mammographic case scoring across different racial and breast density groups. The study emphasizes the potential of AI to provide equitable and reliable screening results, regardless of the patient's race or breast tissue density, two factors known to impact traditional mammography outcomes. For women with non-dense or fatty breast tissue, a low case score corresponded to a significantly lower frequency of cancer (1 in 11,363) compared to women with dense breast tissue who had a low case score (1 in 1,952). Although this finding was not statistically significant according to the Mann-Whitney U test, the difference between categories is notable, and the lack of statistical confirmation is likely due to the low absolute number of cancer cases in the low case score, non-dense cohort. Therefore, the negative predictive value of a low case score on a screening mammogram is presumably higher in women with non-dense breast tissue across a large dataset, suggesting a more reliable assessment for this group. GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer The research analyzed a two-site case-cohort of women aged 30-90 in a population-based screening study in Minnesota and the KARMA cohort from Sweden using an image-derived AI-risk model compared with the clinical Tyrer-Cuzick v8 model using clinical guidelines. Analyses were performed for risk of all breast cancer and restricted to invasive cancer alone. Using the National Institute for Health and Care Excellence (NICE) guidelines, considering women at 8% as high risk, 32% of breast cancers could be subject to preventive strategies in the 9.7% of women at high 10-year risk based on the AI risk model, the 10-year image-derived AI-risk model showed good discriminatory performance and calibration in the two case-cohorts and, showed a significantly higher discriminatory performance than the clinical Tyrer-Cuzick v8 risk model in KARMA. Demonstrating the image-derived AI-risk model has the potential for clinical use in primary prevention and targets up to one third of breast cancers. Join Us at SABCS 2024 Attendees are invited to view these posters during Poster Session 2 on December 11, 2024, from 5:30 to 7:00 p.m. CST. To learn more about iCAD's AI solutions, including the ProFound AI Breast Health Suite, visit iCAD's website or contact iCAD for an interview at SABCS. About iCAD, Inc. iCAD, Inc. ICAD is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. ProFound Detection v4 is FDA Cleared. ProFound AI v3 is FDA Cleared. CE Marked. Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed. Solutions may not be available in all geographies. Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov. CONTACTS Media Inquiries: pr@icadmed.com Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations icad@imsinvestorrelations.com ICADicad Inc$1.88-0.53%WatchlistOverviewMarket News and Data brought to you by Benzinga APIs
[4]
CORRECTION " iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 By Investing.com
NASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD (NASDAQ:ICAD), Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark SecondReadAI by Lunit, Inc. The corrected release follows: iCAD, Inc. (NASDAQ: ICAD) (iCAD or the Company), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions. iCAD and Cascaid Health Partner to Expand Access to AI-Driven Breast Health In alignment with their vision to enable all women to access to AI-powered breast health services, iCAD and Cascaid Health will unveil their collaboration to integrate the ProFound AI Breast Health Suite into Cascaid's leading edge digital health marketplace and access to care platform. Scheduled for beta launch in Q1 2025, this partnership between iCAD and Cascaid Health will launch ProFound Health, a virtual care model powered by Cascaid. ProFound Health will enable women who have not otherwise received an AI-read on their screening mammogram to access iCAD's advanced breast health technology. The initiative reflects both companies' dedication to democratizing access to life-saving technology and creating a world where cancer can't hide. ProFound Health partnership will offer virtual second reads of mammograms leveraging ProFound AI Breast Health Suite, an AI service providing patients without access to AI an opportunity to receive enhanced breast health insights. The initial service will include a second read detection, breast density assessment, and cancer risk evaluation from a Cascaid-affiliated specialist network of clinical experts in women's health through Cascaid's seamlessly integrated digital platform. By combining AI insights with expert clinical reviews, ProFound Health ensures that patients everywhere, regardless of location, can receive precision screening and personalized care. ProFound Health empowers patients with access to critical information about their mammograms and overall breast health, allowing them to make informed decisions and take control of their care journey, said Dana Brown, CEO and President of iCAD. Our collaboration with Cascaid Health's network of clinicians and AI-powered solutions is part of our ongoing commitment to bridging gaps in breast cancer care, ensuring all patients everywhere can access the accuracy and timeliness of AI solutions, and ultimately transforming patient outcomes. We believe that every woman should have access to the best possible information about her breast health and a high quality, personalized care plan to catch cancer early or prevent it altogether. Through our partnership with iCAD, we're addressing a critical need to improve access to advanced breast health services, said Dr. Candace Westgate, Director of Women's Health for Cascaid Health. ProFound Health is more than just a technological innovation, it's a lifeline that empowers patients and healthcare providers with actionable insights, bridging care gaps and ensuring equitable access to precision screening and personalized breast cancer care. Advancing Next (LON:NXT) Generation AI Breast Health Solutions at RSNA 2024 In addition to ProFound Health, iCAD will feature its flagship ProFound Detection Version 4.0, which recently received FDA clearance. This next-generation AI solution enhances breast cancer detection by incorporating prior exams into current analysis, improving the detection of aggressive cancers by 22%, reducing cases with no marks by 18%, and providing clinicians with more reliable insights for better decision-making. Every two minutes, someone loses their life to breast cancer"a disease affecting over 2.3 million women annually. Early detection is critical, as five-year survival rates exceed 99% for stage 1 disease. Yet traditional mammography misses over 20% of breast cancers, particularly in dense tissue, resulting in potentially avoidable late-stage diagnoses, said Dana Brown, President and CEO of iCAD, Inc. ProFound Detection Version 4 revolutionizes breast cancer detection by uniquely integrating prior exams into its analysis. This advanced capability enhances sensitivity, sharpens precision, and provides radiologists with a deeper, longitudinal view of a patient's breast health. By enabling earlier and more accurate detection, especially in dense tissue, ProFound Detection Version 4 sets a new standard in breast health AI, empowering providers to improve outcomes and save lives. Together with our strategic partnerships, we are advancing the fight against cancer and making a meaningful difference for patients worldwide. ICAD'S RSNA 2024 Program Highlights AI-Powered Insights: Advancing Cancer Detection The integration of ProFound AI alongside our nine dedicated breast radiologists has demonstrated remarkable improvements in cancer detection and patient outcomes across our imaging network, said Dr. Kathy Schilling, Medical (TASE:PMCN) Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital. We've seen a 23% overall increase in cancer detection rates, a 4% rise in invasive cancer detection, and doubled rates of lobular cancer detection. ProFound AI also enhanced detection in dense breast tissue by 32%, reduced invasive cancer size by 12%, and lowered histopathologic stage with a 40% reduction in T2 tumors"all without increasing DCIS diagnoses or recall rates. These advancements underscore the transformative potential of AI in improving early breast cancer detection, elevating patient care, and ultimately saving lives. iCAD will be hosting a customer appreciation event, "AI in the Sky: Discover ProFound Insights & Breast Health Innovations," on Sunday, December 1, at 6:00 PM at VU Rooftop in Chicago. Network (LON:NETW) with industry experts, hear insights from key opinion leaders including iCAD's CEO and Board of Directors, and explore how iCAD's solutions are transforming breast health. Visit the iCAD RSNA 2024 event page for the latest updates, event details, and partnership announcements. About Cascaid Health Cascaid Health Inc. delivers a personalized, expert-driven proactive and preventative approach, supported by an integrated platform designed to promote longevity, detect issues early, reverse risks, and optimize healthspan for all. The company's platform offers a curated marketplace featuring innovative products, services, and access to world-class multidisciplinary experts in women's health, precision health, lifestyle medicine, wellness, and performance. Cascaid Health Inc. is committed to advancing health equity, ensuring that cutting-edge healthcare solutions are accessible to everyone. About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking Statements Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI ®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Share
Share
Copy Link
iCAD presents groundbreaking AI-driven breast cancer research at SABCS 2024 and unveils new partnerships and FDA-cleared technologies at RSNA 2024, advancing early detection and risk assessment across diverse populations.
iCAD, Inc. (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, announced the presentation of four novel AI-driven breast cancer research abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) 1. The research focuses on improving detection and risk prediction accuracy while assessing disparities across diverse populations.
Three research abstracts presented by Dr. Chirag R. Parghi, Chief Medical Officer at Solis Mammography, highlight significant advancements:
An AI algorithm for identifying Breast Arterial Calcifications (BAC) showed that BAC prevalence increases with age but doesn't vary by race, suggesting its potential as a universal cardiovascular biomarker 1.
An AI-driven short-term breast cancer risk assessment score demonstrated effectiveness across race and breast density, potentially addressing gaps in traditional mammography 1.
AI-based mammographic case scoring showed consistency across different racial and breast density groups, indicating potential for more equitable screening results 1.
Additionally, Dr. Mikael Eriksson from Karolinska Institute presented research on a 10-year image-derived AI-risk model based on iCAD's ProFound Risk solution, which outperformed the clinical Tyrer-Cuzick v8 risk model 1.
At the Radiological Society of North America (RSNA) 2024 Annual Meeting, iCAD showcased its latest breast health AI technologies 2:
FDA-cleared ProFound Detection Version 4: This next-generation AI solution incorporates prior exams into current analysis, improving aggressive cancer detection by 22% and reducing cases with no marks by 18% 2.
Partnership with Cascaid Health: The collaboration will launch ProFound Health, a virtual care model enabling women to access AI-powered breast health services. This initiative aims to democratize access to advanced breast health technology 2.
Dr. Kathy Schilling, Medical Director at Boca Raton Regional Hospital, reported significant improvements in cancer detection rates after integrating ProFound AI:
These advancements address critical gaps in breast cancer screening, particularly for women with dense breast tissue, where traditional mammography often falls short 2.
The research and technological advancements presented by iCAD at SABCS and RSNA 2024 demonstrate the potential of AI to revolutionize breast cancer detection and risk assessment. By providing more accurate, consistent, and equitable screening results across diverse populations, these AI solutions could significantly improve early detection rates and patient outcomes in breast cancer care.
Reference
[1]
iCAD, Inc. showcases groundbreaking AI technologies for breast health at RSNA 2024, including FDA-cleared ProFound Detection Version 4 and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions.
2 Sources
2 Sources
iCAD, a leader in AI-powered cancer detection, sets date for Q3 2024 financial results and plans to attend the Craig-Hallum Alpha Select Conference, showcasing its commitment to AI innovation in healthcare.
2 Sources
2 Sources
iCAD, Inc., a global medical technology leader in cancer detection and therapy solutions, announces its participation in the upcoming iAccess Alpha Buyside Best Ideas Fall Conference 2024. The company's CEO, Stacey Stevens, will deliver a virtual presentation on September 12, 2023.
2 Sources
2 Sources
Several companies, including iCAD, SKYX, Acrivon Therapeutics, and Janover, have reported their second quarter 2024 financial results. While some companies showed growth, others faced challenges in revenue and net losses.
6 Sources
6 Sources
DeepHealth, a RadNet subsidiary, launches new AI-powered solutions for medical imaging at RSNA 2024, including SmartTechnology™ innovations and collaborations with industry leaders to improve healthcare efficiency and patient care.
13 Sources
13 Sources
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved